RK,
Depends on your description of very expensive. The pharmacy we deal with charges $89 for a 1,000u vial of Humalog. Since the shelf life is 28 days after opening and only one of my clients ever used over 36 units a day, the average compliant diabetic will spend less than $1,200 per year for Humalog. To my knowledge all insulin needles are small gauge with different lengths available. What we get as a standard is 29 gauge with 1/2" length. The smallest I have used is 31 gauge with 5/16" length. Again, to my knowledge, any liquid insulin can be injected with any insulin syringe.
Thought I covered my opinion on competition, generic or otherwise in previous post.
Over the past three years, I am very impressed with Halozyme management and science. They have met every timeline, goal that they are in complete control of. Because of you I did a bit of research on Biodel but don't claim to know too much about them. I do know HALO can and is using over 50 years of bovine research along with its own rhuPH20 research to support the clinical developement and do not see HALO having to jump through the same hoops as Biod. Is Biodel's delivery product FDA approved? If memory serves, it is not.
Depends on your description of very expensive. The pharmacy we deal with charges $89 for a 1,000u vial of Humalog. Since the shelf life is 28 days after opening and only one of my clients ever used over 36 units a day, the average compliant diabetic will spend less than $1,200 per year for Humalog. To my knowledge all insulin needles are small gauge with different lengths available. What we get as a standard is 29 gauge with 1/2" length. The smallest I have used is 31 gauge with 5/16" length. Again, to my knowledge, any liquid insulin can be injected with any insulin syringe.
Thought I covered my opinion on competition, generic or otherwise in previous post.
Over the past three years, I am very impressed with Halozyme management and science. They have met every timeline, goal that they are in complete control of. Because of you I did a bit of research on Biodel but don't claim to know too much about them. I do know HALO can and is using over 50 years of bovine research along with its own rhuPH20 research to support the clinical developement and do not see HALO having to jump through the same hoops as Biod. Is Biodel's delivery product FDA approved? If memory serves, it is not.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
Recent HALO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 10:35:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/23/2026 08:16:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/23/2026 08:13:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/23/2026 08:11:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:32:00 PM
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer • PR Newswire (US) • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:18:04 PM
- U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma • PR Newswire (US) • 03/06/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:56:16 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:51:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:04:55 PM
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 02/17/2026 09:01:00 PM
